


A**CoBRA analysis of 32 genes
in cell lines**

CELL LINES	
ABT1	0/5 (0%)
BARHL2	2/8 (25%)
BUB3	0/9 (0%)
CCNJ	0/6 (0%)
CD44	3/6 (50%)
CDH24	0/9 (0%)
CENPJ	0/9 (0%)
CIDE-A	7/8 (86%)
COMP	4/6 (67%)
DBC1	2/6 (33%)
DDEF2	0/6 (0%)
DLGAP1	5/5 (100%)
EMILIN2	5/9 (56%)
EPSTI1	5/6 (83%)
FBLN2	3/5 (60%)
FOXF2	6/9 (67%)
FOXQ1	1/6 (17%)
GSC	3/9 (33%)
KLF11	0/9 (0%)
KLF13	0/6 (0%)
LYPD5	3/6 (50%)
MAD1L1	0/6 (0%)
NRXN2	2/6 (33%)
ONECUT1	0/9 (0%)
PAX9	4/5 (80%)
PHF2	0/6 (0%)
POU4F1	6/8 (75%)
SALL1	4/6 (67%)
SALL3	3/4 (75%)
SESN3	6/6 (100%)
SIM2	7/7 (100%)
TP53INP1	3/6 (50%)

**B****CoBRA analysis of 16 genes
in primary tumours**

PRIMARY TUMOURS	
CD44	1/24 (4%)
CIDE-A	21/40 (53%)
COMP	20/33 (61%)
DBC1	8/31 (26%)
EMILIN2	16/36 (44%)
EPSTI1	13/36 (36%)
FBLN2	13/38 (34%)
FOXF2	5/35 (14%)
GSC	1/40 (3%)
NRXN2	0/12 (0%)
PAX9	8/39 (21%)
POU4F1	4/27 (15%)
SALL1	25/40 (63%)
SESN3	7/10 (70%)
SIM2	24/29 (83%)
TP53INP1	0/18 (0%)

Figure 1